Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ipilimumab/Nivolumab in Recurrent Resectable Melanoma
NCT06365619Phase 2Withdrawn
- Sponsor
- University of Utah
- Start
- Oct 2026
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in melanoma, sponsored by University of Utah. Planned start Oct 2026; status: withdrawn.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06365619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365619.